South and Central America Custom Antibody Market
Published On: Jul 2021
Published On: Jul 2021
Antibody Development Segment has the Largest Share of Service in the South and Central America Custom Antibody Market during 2021–2028
According to a new market research study on “South and Central America Custom Antibody Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Service, Type, Source, Research Area, and End User,” is expected to reach US$ 45.9 million by 2028 from US$ 23.9 million in 2021. The market is estimated to grow at a CAGR of 9.8% from 2021 to 2028. The report provides trends prevailing in the South and Central America custom antibody market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high demand in research, market consolidations strategies adopted by biotechnology companies, and production and development services offered by custom antibody providers are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the high cost of production.
Although the impact of Covid-19 on antimicrobial resistance is currently impossible to predict, most studies describe extensive empirical use in contrast to a low frequency of bacterial co-infection and secondary infections. Antimicrobial exposure is a risk factor for microbial resistance development. Furthermore, prolonged hospitalization with intensive care unit stays raises the risk of infections with multidrug-resistant bacteria. Antimicrobial stewardship is one of the most critical measures for lowering this risk. Moreover, in March 2020, Hi Technologies, a Curitiba-based biotech firm, launched a test to detect coronavirus (Covid-19). The test is performed using a person's blood sample in the form of a capsule into the Nespresso-like machines. Its system is set to identify the antibodies that are reacting to coronavirus. According to SINDUSFARMA, the pharmaceutical sector in Brazil is highly robust. Every manufacturer can compete with any major corporation in the world's key markets. So much so that national enterprises now account for 65 percent of the market. Cimed also produces more than 10% of pharmaceuticals, with 450 million boxes in a $4 billion market. We also create 7 billion drugs in dosages. Almost every resident receives a dosage. In addition, the facility focuses on the areas of medical research during the COVID pandemic.
The market for custom antibody market is segmented into service, type, source, research area, and end user. Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, antibody fragmentation and labelling. In 2020, the antibody development segment held the largest share of the market, also the same segment is estimated to grow at a significant CAGR due to growing focus of researchers on high-quality custom antibodies for reproducibility during the forecast period.
Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Merck KGAA, Abcam, Genscript, and Agilent Technologies, Inc. are among the leading companies in the South and Central America custom antibody market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2020, Thermo Fisher Scientific has entered into collaboration with WuXi Diagnostics and the Mayo Clinic to develop ELISA test for detection of IgM and IgG antibodies to the novel coronavirus.
The report segments the South and Central America Custom Antibody market as follows:
By Service
By Type
By Source
By Research Area
By End User
By Country
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
